Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway

Mark B. Zimering *

Endocrinology, Veterans Affairs New Jersey Healthcare System, East Orange, New Jersey; Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey.

Introduction

Obesity and inflammation are risk factors for certain diabetes-related neurovascular complications although the underlying mechanism is unclear. Diabetic nephropathy is characterized by increased micro vascular permeability [1] (e.g. micro- and maco-albuminuria) and inflammation thought to drive the progression to end-stage-renal disease (ESRD) [2]. In a prior study in 305 diabetic nephropathy patients, we reported that albuminuria interacted significantly with endothelial cell inhibitory autoantibodies in predicting the risk of substantial decline in renal function, ESRD or death during three-five years’ randomized treatment in the VA NEPHRON D– a clinical trial comparing angiotensin receptor blocker (ARB) alone vs. combined ARB and angiotensin-converting enzyme inhibitor medications [3,4]. Endothelial cell (EC) inhibitory autoantibodies were also increased in subsets of diabetic patients suffering with specific co-morbidities including: diabetes, schizophrenia and the co-morbid clusters: painful neuropathy/maculopathy/nephropathy obstructive sleep apnea/atrial fibrillation/dementia and primary open-angle glaucoma/dementia [5-9]. Mechanistically, potent endothelial cell autoantibodies caused apoptosis through a mechanism involving large, sustained increases in intracellular Ca2+ leading to caspase-3 activation [10].
autoantibodies caused neurite retraction, and prolonged N2A neuroblastoma cell depolarization [8]. A subset of dementia/glaucoma autoantibodies caused contraction and process retraction in cerebral cortical astrocytes [9]. The pleiotropic actions of the diabetic neurovascular autoantibodies led us to test (in the present study) whether endothelial cell- and neurotoxic diabetic autoantibodies may target a specific subclass of G-protein coupled receptors (GPCR) linked to increases in intracellular Ca2+.

Participants & Methods

Participants

Informed consent for the Investigational Review Board-approved, local, Veterans Affairs New Jersey Healthcare System proposal was obtained from all study patients prior to blood drawing. Baseline clinical characteristics in the study participants are shown in (Table 2). The cohort was comprised of older men, having a mean age of 68 years, average BMI of 38 kg/m2, average duration of type 2 diabetes of 13.8 years, and mean glycosylated hemoglobin of 7.6%. In order to explore possible linkages between autoantibodies, obesity, inflammation and diabetic neurodegenerative or vascular complications, patients were selected on the basis of a high concordance (in individual patients) of these same risk factors and complications. Overall, the cohort had a high prevalence of neurodegenerative disorder(s) (64%), [i.e. major depression (n=5), Parkinson’s disease (n=2), glaucoma (n=1)], nephropathy (82%), moderate-or severe-risk obesity (82%), and one or more conditions linked to inflammation, e.g. atrial fibrillation (64%), autoimmune thyroid disease (27%), obstructive sleep apnea (45%). Nine of eleven moderate-severely obese patients had an average of two or more complications (atrial fibrillation, obstructive sleep apnea, painful neuropathy) associated with inflammation. Our underlying hypothesis is that diabetic nephropathy drives autoantibody production through the release of endothelial cell auto antigens in the setting of chronic inflammation. As a test of this hypothesis, all but two study patients had diabetic nephropathy. Moderate-severely obese patients were selected for this mechanistic study, since in prior reports, obesity was significantly associated with pathologies (e.g. atrial fibrillation, obstructive sleep apnea) in which neurotoxic plasma autoantibodies were present at increased levels compared to control diabetic patients [8].

Table 1: Autoantibodies in diabetes having co-morbid neurovascular complications: spectrum of autoantibody-mediated effects [5,6,7,8,9]

<table>
<thead>
<tr>
<th>Complication</th>
<th>Autoantibodies</th>
<th>Autoantibodies Endothelial cell</th>
<th>Neurons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nephropathy</td>
<td>Incr vs. control</td>
<td>Inhibit/stim survival</td>
<td>Neurite retraction, depolarization</td>
</tr>
<tr>
<td>Painful Neuropathy</td>
<td>Incr vs. control</td>
<td>Inhibit survival</td>
<td>Neurite retraction</td>
</tr>
<tr>
<td>Depression</td>
<td>Incr vs. control</td>
<td>Inhibit survival</td>
<td>N2A &amp; DG NPC retraction, depol</td>
</tr>
<tr>
<td>Glaucoma</td>
<td>Incr vs. control</td>
<td>Inhibit survival</td>
<td>Neurite retraction, astrocytes effects*</td>
</tr>
<tr>
<td>Parkinson’ disease</td>
<td>Incr vs. control</td>
<td>Inhibit/stim survival</td>
<td>Neurite rtrct/outgrowth [30]</td>
</tr>
<tr>
<td>Obstr sleep apnea</td>
<td>Incr vs. control</td>
<td>NT</td>
<td>N2A neurite retraction, depolarization</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>Co-morbid with OSA</td>
<td>NT</td>
<td>N2A depolarization</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>Incr vs. control</td>
<td>Inhibit</td>
<td>N2A neurite retraction, depolarization</td>
</tr>
</tbody>
</table>

*Autoantibodies in diabetic primary open-angle glaucoma and dementia caused contraction and process shortening in cerebral cortical astrocytes [9]. Obstr (active); Incr (eased) compared to Control diabetes populations lacking this complication; stim (ulate); NT- not tested; N2A mouse Neuroblastoma cell line; rtrct (retraction), cntr (contraction); short (ening), depol (arization), DG dentate gyrus, NPC-neural progenitor cell, *i.e. “NPC-neural progenitor cell, OSA- obstructive sleep apnea.

Diagnostic methods and subgroups

Depression

All patients having a diagnosis of major depression were evaluated by psychiatry staff at the Veterans Affairs New Jersey Health Care System as previously reported [5]. Painful diabetic neuropathy is defined according to previously reported criteria [7]. Diabetic nephropathy is defined as persistent micro- or macro-albuminuria, the latter urinary albumin excretion > 300 mg/g creatinine or urinary protein excretion > 500 mg/g creatinine.

Morbid obesity

Morbid obesity is defined as body mass index (BMI) > 40 kg/m². Moderate-severe obesity is defined as BMI > 35 kg/m². Pt 1: A 71-year-old male with BMI 48 kg/m², diabetic nephropathy, atrial fibrillation, obstructive sleep apnea (OSA), glaucoma, depression, and painful neuropathy.

Parkinson’s disease (PD)

PD 1: A 70-year-old male with diabetic nephropathy, atrial fibrillation, obstructive sleep apnea, Parkinson’s disease and painful neuropathy.

PD 2: A 79-year-old male with diabetic nephropathy, autoimmune thyroid disease, and Parkinson’s disease.

Cell Culture

Bovine pulmonary artery (BPA) endothelial cells (Sigma, St. Louis, MO) were maintained at 37°C in 5% CO2/95% air in Medium 199 plus 10% fetal calf serum. BPA endothelial cells were passaged continuously and used between passages 4-10.

Endothelial Cell Growth Assays

Endothelial cell number assays were carried out as previously reported [11]. After 48 hours’ incubation in the presence of protein-A-eluate fractions, cell number, i.e. cell-associated acid phosphatase activity, was determined as previously described.
Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway

[11]. Growth-promoting activity (determined in quadruplicate for each test factor) is expressed as a percentage of the control cell number (determined in quadruplicate) for cells grown in the absence of protein-A eluate fractions.

**Protein A Affinity Chromatography**

Protein A chromatography was carried out as previously described [11]. Eluate fractions were stored at 0-4 degrees C. All fractions were sterile filtered (Millipore Corp., Bedford, MA; 0.22um) before assay for growth-promoting activity.

**Mouse N2A cells**

Mouse N2A neuroblastoma cells were cultured as previously described [6].

**Neurite retraction assays**

Mouse N2A cells were plated at low density in 35 mm dishes. After one to two days incubation at 37 degrees C, protein A-eluate fractions (7-10 µg/mL) from diabetic pathologies’ plasma were added in the presence or absence of GPCR antagonists or antagonists of downstream signaling molecules or an intracellular calcium chelator. Thin neurite length was estimated (at baseline and again after 25 minutes exposure to added fractions) as the average length in all thin neurites (having diameter of ~ 0.5-1 microns) extending at least 2 cell diameters from the cell body at baseline in each of 5-10 cells. Percent of antibody-induced neurite retraction is expressed as a percent of acute neurite length-shortening (observed after 25 minutes) in cells exposed to test factors plus autoantibodies compared to identical concentration of same autoantibodies alone. Each point represents the mean of two or more determinations which generally varied by < 15%.

**N2A survival assays**

N2a cells were plated at 10⁴-10⁵ cells/cm² in 96 cell plates in DMEM plus 10% fetal calf serum. After 2-3 days incubation, test fractions were added to cells in quadruplicate. Following (8 or 24 hours) incubation at 37 degrees C, cell survival was determined using MTT assay. Twenty micro liters of a 5 mg/mL MTT solution in PBS was added to each well; after 3.5 hours incubation at 37 degrees C, MTT solution was discarded and 200 micro liters DMSO was added to each well. After 10 minutes, absorbance was determined at 570 nm. Cell survival is expressed as a percentage of the absorbance in control N2A cells to which no test factors were added.

**Adult neural progenitor cells**

The stem cells were originally isolated from the dentate gyrus of adult Fisher 344 rats and were obtained from Dr. Fred Gage at the Salk Institute. The NPCs were cultured as previously described [5]. Test protein-A eluate fractions from diabetic pathology plasma (5-7 µg/mL protein) was added to cells on DIV 3. Acute process shortening and cell contraction were determined by continuous observation (at 5 minute intervals) using a Nikon inverted microscope at 200X magnification for up to 75 minutes after adding test factors.

**Chemicals**

M100907, ketanserin, spiperone, DOI, bosentan, losartan, prazosin, U73211, BAPTA-AM, 2-APB were obtained from Sigma Chemical Co. (St Louis, MO.) All other chemicals and reagents were analytical grade.

**Protein Determinations**

Protein concentrations were determined by a bicinchoninic acid protein assay kit (Pierce Chemical Co., Rockford,IL).

**Statistics**

All data are the mean ± SD (Tables 1, 2, 4) or SEM (Figure 4-7) as indicated. Comparisons were made by Student’s t-test for a continuous variable with a significance level, p=0.05.

<table>
<thead>
<tr>
<th>Table 2: Baseline clinical characteristics in study cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk factor</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
</tr>
<tr>
<td>Diabetes Duration (years)</td>
</tr>
<tr>
<td>HbA1c (%)</td>
</tr>
<tr>
<td>Nephropathy (yes/no)</td>
</tr>
<tr>
<td>Atrial fibrillation (yes/no)</td>
</tr>
<tr>
<td>Obstructive sleep apnea (yes/no)</td>
</tr>
<tr>
<td>Painful neuropathy (yes/no)</td>
</tr>
<tr>
<td>Autoimmune thyroid disease (yes/no)</td>
</tr>
<tr>
<td>Neurodegenerative disease* (yes/no)</td>
</tr>
<tr>
<td>* Depression (n=5), Parkinson’s disease (n=2).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3: Pharmacologic profile of endothelial cell-inhibitory activity in diabetes autoantibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antagonist [Conc]</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>M100907 [2 µM]</td>
</tr>
<tr>
<td>M100907 [200 nM]</td>
</tr>
<tr>
<td>M100907 [100 nM]</td>
</tr>
<tr>
<td>Ketanserin [100 nM]</td>
</tr>
<tr>
<td>Prazosin [1µM]</td>
</tr>
<tr>
<td>Losartan [10µM]</td>
</tr>
<tr>
<td>Bosentan [10 µM]</td>
</tr>
<tr>
<td>CTEP [10 µM]</td>
</tr>
</tbody>
</table>

A1-AR- alpha 1 adrenergic receptor; AT-1R- angiotensin II, type 1 receptor; ET-AR- endothelin A receptor, mGlu-5R- metabolic glutamate 5 receptor


Page 3 of 10
Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/ Ca2+ Pathway

### Results

**Effect of diabetic autoantibodies in rat dentate gyrus neural progenitor cells** Rat dentate gyrus (DG) neural progenitor cells (NPC) were sensitive to low concentrations of diabetic depression autoantibodies (5-7 µg/mL) and were previously reported to cause both NPC process retraction and decreased cell survival [5]. In the present study, diabetic autoantibodies (8 µg/mL = 80 nM) from a patient suffering with nephropathy, Parkinson’s disease, atrial fibrillation and painful diabetic neuropathy (i.e. PD 1) caused rapid NPC neurodegeneration in distal fine processes after 15 minutes’ incubation. After 20-25 minutes exposure, proximally-located processes extending from cell bodies had undergone dendritic simplification and beading. After 65 minutes, several NPC cell bodies appeared highly refractile- a characteristic of dying cells. Pre-incubation (for 5 minutes) with M100907 at 2 µM concentrations completely prevented early NPC neurodegeneration (during 30 minutes’ observation) in identical concentrations (80 nM) of the PD, Pt 1 autoantibodies. Ten-fold lower M100907 (200 nM) concentrations partially protected against PD, Pt 1 autoantibody-induced early NPC neuro degeneration in proximal dendrites. Twenty nanomolar M100907 had no significant protective effect on either proximally- or distally-located processes.

### Effects of diabetic autoantibodies on N2a neuroblastoma cells morphology and survival:

#### Neurite retraction

The effect of IgG autoantibodies on acute length-shortening in N2A neuroblastoma thin dendrites was examined at five-minute intervals using time-lapse microscopy (Figure 1). Significant neurite retraction was evident as early as ten-fifteen minutes after application of 10 microgram per milliliter concentration of diabetic autoantibodies from two different patients (Figure 1). After 25 minutes, identical concentration of Pt 1 (a morbidly obese diabetic patient (BMI 48 kg/m2) suffering with nephropathy, depression, obstructive sleep apnea, painful neuropathy, and atrial fibrillation) IgG caused mean N2A thin neurite length reduction of 68% (average of ten cells each having 2-10 processes, not shown in Figure 1). Pre-incubation (for 5 minutes) with 200 nM concentrations of M100907, a highly selective 5-HT2A receptor antagonist, was ~ 94% protective against IgG-induced process length reduction (assessed after 25 minutes’ exposure time). M100907 at (5-2000 nM) concentrations caused a dose-dependent inhibition of process length shortening in identical concentrations of Pt 1 IgG (Figure 2A). A log-log graph of the percent change in process length versus M100907 concentration was linear, had a slope of unity (Figure 2B) and IC50 = 39 nM. Ketanserin, a moderate affinity, selective 5-HT2A receptor antagonist, and siperone, a high affinity, less selective 5-HT2AR antagonist, both caused dose-dependent inhibition of Pt 1, IgG-induced neurite length shortening (Figure 3A-B). The IC50 calculated from log-log plots for ketanserin and siperone were 215nM and 50 nM, respectively, consistent with the order of binding affinities of the three antagonists for the 5HT2A receptor; i.e. M100907 > siperone > ketanserin [12].

Saturating (1 µM) concentrations of 2,5-dimethoxy-4-iodoamphetamine (DOI), a 5HT-2A receptor agonist, caused...
Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/ Ca2+ Pathway

Figure 2: Dose-dependent inhibition of diabetic autoantibody, N2a neurite retraction by M100907, a highly selective 5-HT2AR antagonist. Patient 1 autoantibodies (10 µg/mL) were incubated with N2A cells in the presence or absence of (5-2000 nM) concentrations of M100907. A) Percent of autoantibody-induced neurite retraction was determined as described in Methods. B) Log-log plot of (% of antibody retraction) vs. log M100907 concentration is linear with a slope of unity indicative of a homogeneous population of 5-HT2A receptors.

Figure 3: Dose-dependent inhibition of diabetic autoantibody (Pt 1, 10 µg/mL), N2A neurite retraction by A) ketanserin, a selective 5-HT2AR antagonist, or B) spiperone, a high affinity, less selective 5-HT2AR antagonist. Percent of autoantibody-induced neurite retraction was determined as described in Methods.

blocked by pre-incubations with (50 µM) concentrations of the inositol 1,4,5-trisphosphate (IP3) receptor antagonist 2-aminoethoxydiphenyl borate (2-APB) or (10 µM) RhoA/Rho kinase inhibitor Y27632 (Table 4). It was also completely blocked by pre-incubation (15 mins) with (30 µM) Ca2+ chelator, BAPTA-AM. Ten micromolar concentrations of Y27632 and fifty micromolar 2-APB not only completely prevented autoantibody neurite retraction, but they caused significant neurite lengthening consistent with suppression of basal GPCR, Gαq/11 activation. Taken together, these data suggest involvement of the PLC-γ/IP3R/Ca2+ pathway (which positively couples to Gαq/11 and 5-HT-2A receptor) in the mechanism of diabetes autoantibodies-dependent neurite retraction.

N2A accelerated cell death (after 8 hours incubation) with autoantibodies from three different diabetic patients was significantly prevented by co-incubation with (non-toxic) 1 µM concentrations of the IP3R inhibitor 2-APB (Figure 5C) suggesting involvement of sustained Ca2+ release in the mechanism of neuroblastoma cell death.

**Figure 4:** Effect of GPCR antagonists on diabetic autoantibody-induced accelerated N2A cell loss. N2A neuroblastoma cell autoantibody-induced accelerated loss was A) completely prevented by co-incubation with 200 nM concentrations of M100907, B-C) lack of significant protection by co-incubation with 200 nM ketanserin(B) or 100 nM prazosin (C). N2A cells were incubated in the presence of absence of specific GPCR antagonists for 24 hours at 37 degrees C; cell number was determined as described in Methods. Results are the mean ± SEM. NS- not statistically significant.

**Figure 5:** Effect of 5-HT-2AR agonist (DOI) on N2A survival in the absence (A-B) or (B) presence of diabetic autoantibodies; C) effect of 2-APB (inositol triphosphate 3 receptor antagonist) on N2A survival in the presence of diabetic autoantibodies. N2A cells were incubated for 24 hours (A-B) or for 8 hours (C) at 37 degrees C; cell number was determined as described in Methods. Results are the mean ± SEM. NS- not statistically significant.

**Effect of diabetic autoantibodies on endothelial cell survival**

M100907 at (200-2000 nM) concentrations completely protected endothelial cells from cell death induced by diabetic Parkinson’s disease (10 µg/mL) (Figure 6A) or diabetic depression autoantibodies (not shown in Figure 6A). Lower M100907 concentrations (50-100 nM) caused dose-dependent significant (16-27%) protection (Figure 6B) against diabetic Parkinson’s disease.
The autoantibodies (10 µg/mL) of the first Parkinson's disease patient (PD1) promoted endothelial cell inhibitory effect in Parkinson's disease, pt 1 autoantibodies (10 µg/mL). C) M100907 (200 nM) completely neutralized EC stimulation from Parkinson's disease, pt 2 autoantibodies (10 µg/mL). Bovine pulmonary artery endothelial cells were incubated in the presence or absence of Parkinson's disease autoantibodies for 48 hours at 37 degrees C; cell number was determined as described in Methods. Results are the mean ± SEM.

Figure 6: Effect of highly selective 5-HT-2AR antagonist M100907 on endothelial cell survival induced by diabetic autoantibodies. M100907 dose-dependently protected against (A,B) endothelial cell survival inhibitory effect in Parkinson's disease, pt 1 autoantibodies (10 µg/mL). C) M100907 (200 nM) completely neutralized EC stimulation from Parkinson's disease, pt 2 autoantibodies (10 µg/mL). Bovine pulmonary artery endothelial cells were incubated in the presence or absence of Parkinson's disease autoantibodies for 48 hours at 37 degrees C; cell number was determined as described in Methods. Results are the mean ± SEM.

Figure 7: Effect of M100907 (A) or other GPCR antagonists (B,C) on Parkinson's disease Pt 2 autoantibody-induced inhibition of endothelial cell survival. Bovine pulmonary artery endothelial cells were incubated in the presence or absence of Parkinson's disease, Pt 2 autoantibodies (10 µg/mL) for 48 hours at 37 degrees C; cell number was determined as described in Methods. Results are the mean ± SEM. NS- not statistically significant.

These data suggest involvement of a 5HT-2 receptor in the inhibitory effects of diabetic neurovascular autoantibodies on EC survival.

Vascular cells express endothelin A receptor (ET-AR), angiotensin II, type 1 receptor (AT-1R) and metabotropic glutamate 5 receptor (mGlu-5R). Saturating concentrations (10 µM) of each of the specific GPCR antagonists: bosentan (ET-AR), losartan (AT-1R) or CTEP (mGlu-5R) had a modest inhibitory effect on autoantibody-mediated EC survival (Table 3) consistent with GPCR cross-talk, but lack of direct involvement of these receptors in autoantibody-mediated EC survival inhibition.
Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/ Ca²⁺ Pathway

Discussion

The present evidence is the first to suggest that autoantibodies in subsets of diabetes suffering with nephropathy, atrial fibrillation, morbid obesity, depression, and/or Parkinson's disease mediate neural- and endothelial cell- inhibitory effects via 5-hydroxytryptamine-2 receptors. The 5-hydroxytryptamine receptor-2A (5-HT2AR) is expressed in neuroblastoma cells [15]; and 5-HT2AR is the predominant subtype which is highly concentrated in brain regions involved in perception, mood, learning and memory, pain, cognition, appetite, and sleep/ wakefulness [16]. The 5-HT2A receptor is a target of atypical antipsychotic drugs [17], and anti-depressant medications, such as amitriptyline [18], the latter is also useful in the treatment of painful diabetic neuropathy.

We previously reported highly potent neural- and EC-inhibitory autoantibodies enriched in subsets of diabetes having co-morbid depression, schizophrenia and/or painful neuropathy compared to age-matched control diabetic populations lacking these specific complications (Table 1). The finding presented that three different 5HT-2AR antagonists prevented autoantibody-induced acute N2A neurite retraction and displayed an order of potency (M100907 > spiperone > ketanserin) which mirrored their relative affinities for the 5-HT-2AR [12] suggests involvement of 5-HT-2A receptors in diabetic autoantibody-induced neural inhibitory effects.

The 5-HT-2A receptor couples to a Gαq/11 subclass of heterotrimeric G proteins in neurons and other cell types [14]. Following receptor activation, GTP-bound Gaq/11 activates phospholipase C (PLC-γ) which in turn hydrolyzes PIP2 to yield inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 causes release of Ca²⁺ from intracellular stores, the latter plays a role in the activation of protein kinase C. In the current study, specific inhibitors of phospholipase C (PLC-γ), IP3R and an intracellular calcium chelator each nearly or completely prevented acute autoantibody-induced neurite retraction. The selective ROCK inhibitor Y27632 (10 µM) also completely prevented acute autoantibody-induced neurite retraction which suggests that ROCK activation can occur through the coordinated action(s) of activated Gaq/11 and beta (β) - arrestin-1 [19].

Large increases in intracellular Ca²⁺ are known to be toxic to neurons [20]. Substantial protection against accelerated N2A cell death by nontoxic concentration of 2-APB (1 µM) suggests an important role for release of Ca²⁺ from sequestered intracellular stores in the mechanism of accelerated neuroblastoma cell loss.

A striking feature of autoantibody-induced neurite retraction was the absence of its spontaneous cessation, e.g., as occurred in N2A cells exposed to high concentrations of the hallucinogenic 5-HT2A agonist 2,5-dimethoxy-4-iodoamphetamine, (DOI). Beta arrestin-1 and -2 knock-out bearing mouse embryonic fibroblasts displayed 'enhanced agonism' at both the agonistins II receptor and beta adrenergic receptors [21] consistent with a general role for β-arrestins in GPCR- desensitization [14]. The mechanism of diabetic autoantibodies 'long-lasting agonism' at the 5-HT-2AR is unknown. One possibility (which requires more study) is that it may interfere with β-arrestin binding to regulatory domains located in the third intracellular loop of GPCR [22]. Dimeric or oligomeric forms of IgG autoantibodies might preferentially target 5-HT-2A receptor heterodimers in the membrane which (in some cases) are comprised by highly stable non-covalent interactions between oppositely-charged amino acid residues in the intracellular domains of physically neighboringGPCRs [23]. Stable heteromers involving GPCRs positively coupled to Gq/11 heterotrimer G proteins may contribute to sustained activation of PLC/IP3R/Ca²⁺ pathway causing long-lasting Ca²⁺ release (>10 minutes) similar to that which was observed in different subsets of diabetic autoantibodies [8].

The 5-hydroxytryptamine-2A receptor can activate multiple, different signaling pathways depending (in part) on differences in the chemical structure(s) among particular agonist ligands [14]. The ability of a given ligand to activate a specific intracellular signaling pathway downstream of 5-HT-2AR binding has been referred to as 'biased agonism' or 'functional selectivity' [14]. In a prior report in three hundred and five diabetic nephropathy patients from the VA NEPHRON D randomized clinical trial, patients harboring less- inhibitory or mildly-stimulatory EC plasma autoantibodies were at substantially higher risk of experiencing a composite chronic kidney disease (CKD) endpoint, (i.e. significant decline in renal function, end-stage renal disease or death), compared to patients harboring strongly- inhibitory EC plasma autoantibodies [3]. Here, the protein-A eluate in a diabetic CKD, Parkinson's disease patient (i.e. PD2) contained components which evoked either mild EC stimulation or potent EC inhibition and unexpectedly, both kinds of responses were blocked by M100907 suggesting 5-HT-2AR-mediated functional selectivity. Although the precise make-up of the autoantibody ligand(s) is unknown, evidence from prior studies suggests that EC stimulation may have resulted from an immune complex ligand. Autoantibodies in four additional diabetic nephropathy/CKD patients evolved initial EC stimulation and upon re-assay following brief storage, EC inhibition (M. Zimering, unpublished data). These data suggest that immune complexes in diabetic CKD protein-A eluates were less stable (in dilute solution) compared to component IgG. More study is needed to determine whether diabetic CKD autoantibodies may also induce proliferation in mesangial cells, via 5-HT-2A receptors coupled to ERK signaling [24].

The pharmacologic profile of antagonism of diabetic autoantibody-induced accelerated endothelial cell death suggests possible involvement of additional receptor subtypes besides 5-HT-2A. For example, 100 nM ketanserin did not protect against autoantibody-induced endothelial cell death despite having low nanomolar affinity at the 5HT-2A receptor. Since 5-HT-2BR is the predominant 5HT receptor subtype expressed on pulmonary artery endothelial cells [26] and ketanserin has low micro-molar affinity at the 5-HT-2B receptor [25], these data suggest possible involvement of the 5-HT-2B receptor subtype in autoantibody-
mediated accelerated endothelial cell death.

Adult neurogenesis in the dentate gyrus has been shown to correlate with the efficacy of clinical response(s) to various anti-depressant treatments [27]. The present data showing that diabetic autoantibodies inhibit effects on DG NPC cells could be completely prevented by the selective 5-HT-2AR antagonist M100907 is of interest. Adult DG neural progenitor cells express multiple different 5-HT-1 and 5-HT-2 receptor subtypes [28]. The inhibitory effects of long-lasting 5-HT-2R agonist diabetic depression autoantibodies are consistent with a report that chronic (7 days) administration of a 5-HT-2R agonist, α-methyl-5-HT, suppressed newborn DG neuron survival in adult female C57BL/6 mice [28].

The ontology of agonist 5-hydroxytryptamine-2A receptor autoantibodies is unknown. One possibility is endothelial injury which releases sequestered auto-antigens, e.g. basic fibroblast growth factor (bFGF) [29], whose increased concentration in plasma correlated with the spontaneous appearance of agonist FGF-like autoantibodies in various pathologies including cancer subsets [11, 30] and obese type 2 diabetes [31]. Vascular injury also causes platelets to release serotonin together with polyphosphates, the latter of which, like heparin, is a highly anionic substance capable of binding and protecting (locally-released) bFGF from inactivation [32]. Since platelet activation increases in obesity and inflammation [33], it is possible that repeated vascular injury through the release of sequestered antigens promotes immune response(s) (in susceptible individuals) leading to the formation of agonist 5-HT-2A receptor autoantibodies. Kidney was reported to have among the highest 5-HT-2R mRNA expression levels among peripheral organs [25]. Thus it is possible that 5-HT-2R released through ongoing renal endothelial damage (e.g. in diabetic nephropathy populations) may contribute (in part) to the development of agonist 5-HT-2 receptor autoantibodies.

In summary, diabetic autoantibodies from patients suffering with nephropathy, and/or depression, atrial fibrillation, painful neuropathy or another neurodegenerative disease caused N2A neurite retraction and accelerated neuron loss through a mechanism involving 5-HT-2AR receptors positively coupled to the PLC/IP3/Ca2+ pathway. These findings have relevance for understanding possible role(s) for agonist 5-hydroxytryptamine-2A receptor autoantibodies in pathophysiology in diabetes-related complications affecting brain regions and peripheral organs in which the 5-HT-2 receptor is highly concentrated.

Acknowledgements

Dr. Janet Alder, Dr. Smita Thakker-Varia, and Shavonne Teng (Department of Neuroscience & Cell Biology, Rutgers-Robert Wood Johnson Medical School, Piscataway, New Jersey) for providing the mouse N2A neuroblastoma and rat dentate gyrus neural progenitor cells used in these experiments. Veterans Biomedical Research Institute (East Orange, New Jersey) for grant support to MBZ.

References


Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway


